Tutorials
Biomarin Pharmaceutical Inc logo

Biomarin Pharmaceutical Inc

$ 95.82 +2.84 (+3.05%) 10:08 PM EST
P/E:
368.54
P/B:
3.94
Market Cap:
$ 17.77B
Enterprise V:
$ 17.74B
Volume:
2.10M
Avg Vol (2M):
1.16M
Also Trade In:
Volume:
2.10M
Market Cap $:
17.77B
PE Ratio:
368.54
Avg Vol (2-Month):
1.16M
Enterprise Value $:
17.74B
PB Ratio:
3.94
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Biomarin Pharmaceutical Inc
NAICS : 325412 SIC : 2834
770 Lindaro Street, San Rafael, CA, USA, 94901
Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
Name Current Vs Industry Vs History
Cash-To-Debt 1.03
Equity-to-Asset 0.73
Debt-to-Equity 0.24
Debt-to-EBITDA 6.12
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.07
Distress
Grey
Safe
Beneish M-Score -2.56
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 90.89
9-Day RSI 82.52
14-Day RSI 75.48
6-1 Month Momentum % -2.56
12-1 Month Momentum % 10.82

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.42
Quick Ratio 3.69
Cash Ratio 2.39
Days Inventory 602.7
Days Sales Outstanding 79.02
Days Payable 145.76

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1

Financials (Next Earnings Date:2022-10-27 Est.)

BMRN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:BMRN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1,911.709
EPS (TTM) ($) 0.26
Beta 0.12
Volatility % 25.34
14-Day RSI 75.48
14-Day ATR ($) 2.610546
20-Day SMA ($) 87.254
12-1 Month Momentum % 10.82
52-Week Range ($) 70.73 - 96.5
Shares Outstanding (Mil) 185.45

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biomarin Pharmaceutical Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More